Almac Upgrades API Manufacturing Capacity at Craigavon Plant

Almac currently has six API and advanced chiral intermediates in Phase III clinical development and has been steadily increasing its market penetration in late phase clinical development.

Drug development services provider Almac is expanding its manufacturing capacity at its European headquarters in Craigavon, Northern Ireland to satisfy increasing demand for active pharmaceutical ingredients (APIs).

The upgraded facility will include reactor vessels with state-of-the-art cleanroom product isolation and drying equipment to allow highly potent API (HPAPI) manufacture in up to 600kg batch sizes.

Almac currently has six API and advanced chiral intermediates in Phase III clinical development and has been steadily increasing its market penetration in late phase clinical development.

Denis Geffroy, vp of Business Development at Almac said the capacity increase would allow a smooth t